Price (delayed)
$0.9104
Market cap
$133.27M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.33
Enterprise value
$108.23M
Veru Inc. is an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer and breast cancer. The Veru prostate cancer pipeline includes VERU-111,
There are no recent dividends present for VERU.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.